$VTAK Catheter Precision, Inc. (NYSE American: VTA
Post# of 91
![Avatar](/images/ProfileImages/1556287445_32333_stitch_pleased_avatar_picture_13166.jpg)
https://www.accesswire.com/841419/catheter-pr...ted-states
FORT MILL, SC / ACCESSWIRE / March 11, 2024 / Catheter Precision, Inc. (the "Company"
![](/images/icons/icon_wink.gif)
After using LockeT, Dr. Sajad Hayat said, "A vascular hemostasis [product] should be simple to use and effective. The LockeT venous hemostasis device combines the simplicity of a figure of 8 suture but with a more controlled delivery and release making it ideal. Importantly, it simplifies post procedure care facilitating early mobilization and discharge."
"Not only were the first cases outside of the United States successful, but the value of the product was immediately observed by the physician," said David Jenkins, CEO of Catheter Precision, Inc. "Dr. Hayat was quick to observe that LockeT is not only simple in design, but simple to use and that it effectively creates hemostasis and provides additional benefits to the patient and hospital staff."
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)